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SUMMARY
Background
Several studies have shown that patients with non-erosive reﬂux disease
(NERD) are less responsive to proton pump inhibitors (PPIs) than those
with erosive disease as they belong to different subgroups, in whom factors
other than acid can trigger symptoms.
Aim
To evaluate whether combined therapy (mucosal protection plus acid sup-
pression) would improve symptom relief compared to PPI treatment alone.
Methods
In a multicenter, randomised, double-blind trial, 154 patients with NERD
were randomised to receive Esoxx (Alfa Wassermann, Bologna, Italy), a
hyaluronic acid-chondroitin sulphate based bioadhesive formulation, or pla-
cebo, in addition to acid suppression with standard dose PPIs for 2 weeks.
Symptoms (heartburn, acid regurgitation, retrosternal pain and acid taste in
the mouth) and health-related quality of life (HRQL) were evaluated before
and after treatment. The primary endpoint was the proportion of patients
with at least a 3-point reduction in the total symptom score.
Results
At the end of treatment, the primary endpoint was reached by 52.6% of
patients taking Esoxx compared to 32.1% of those given placebo (P < 0.01).
The same was true also for HRQL, evaluated by means of the Short Form-
36 questionnaire, which improved with both treatments, but some items
were signiﬁcantly better after Esoxx plus PPI therapy.
Conclusion
The synergistic effect of Essox with PPI treatment suggests that mucosal
protection added to acid suppression could improve symptoms and HRQL
in NERD patients.
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INTRODUCTION
Gastro-oesophageal reﬂux disease (GERD) is a highly
prevalent disorder in Western countries, as its predomi-
nant symptom, heartburn, can occur once a week in up
to 26% of the general population.1 Despite geographical
variations, the prevalence of GERD is increasing world-
wide.
Over the past decade, it has been realised that there
are two different phenotypes of the disease. Some
patients present oesophageal mucosal lesions (i.e. erosive
oesophagitis), but the majority (up to 70%) have a
macroscopically normal mucosa at endoscopy. Such
patients are usually considered to have non-erosive reﬂux
disease (NERD).2–4
Proton pump inhibitors (PPIs) represent the ﬁrst
choice medical treatment for GERD,5 in that they are
able to provide an 80–85% healing rate for oesophageal
lesions, including ulcers, and also reduce the incidence
of complications. Pooled analyses6, 7 have shown that in
56–76% of cases, symptom relief can also be achieved,
even though this beneﬁt seems to be reduced in patients
with NERD. According to a widely quoted systematic
review,7 compared to patients with erosive oesophagitis,
patients with NERD display a reduced symptom relief
with PPIs, with about 20% reduction of therapeutic gain.
A large AGA survey8 found that – despite PPI use –
over 55% of subjects with GERD symptoms in the gen-
eral population (where non-erosive and erosive diseases
are obviously mixed) report continued disruption of their
quality of life.
Recent investigations have shown that not only acidic,
but also non-acidic reﬂuxes are able to induce the histo-
pathological alterations, which have been clearly docu-
mented by electron and light microscopy in the majority
of NERD patients.9–11 In particular, the dilation of inter-
cellular spaces between adjacent cells of the oesophageal
epithelium represents a feature that has become the hall-
mark of microscopic oesophagitis. This intercellular gap
leads to increased permeability that favours the penetra-
tion of hydrogen ions and other substances (including
pepsin and bile) into oesophageal sub-mucosa, thus
reaching nerve ﬁbres, whose stimulation generates the
typical symptom heartburn. Several studies12 suggested a
synergistic action between acid and duodeno-gastric
reﬂux in inducing lesions. The important role of pepsin
in the pathogenesis of extra-oesophageal manifestations
of GERD is increasingly being appreciated.13
An ideal therapy for NERD patients should – in addi-
tion to acid secretion – address all the above-mentioned
pathophysiologic features, that is provide a barrier to
(and/or bind) the residual aggressive components of the
reﬂuxate (i.e. weakly acidic content and pepsin) while
stimulating mucosal repair. To achieve these goals, a
class III medical device, Esoxx (Alfa Wassermann,
Bologna, Italy), was speciﬁcally designed and devel-
oped.14, 15 It consists of a mixture (1:2.5 ratio) of low
molecular weight (80–100 kDa) hyaluronic acid and low
molecular weight (10–20 kDa) chondroitin sulphate, dis-
persed in a bioadhesive carrier (poloxamer 407) to form
a macromolecular complex, coating the oesophageal
mucosa and acting as a mechanical barrier against the
noxious components of the reﬂuxate. Transit time of liq-
uids through the oesophagus is very short (less than
16 s), even in a supine subject.16 A viscous liquid formu-
lation that adheres to and coat the mucosa will limit the
contact of reﬂuxed acid and pepsin with the epithelial
surface17 and can act as a vehicle to deliver drugs for
local action within the oesophagus.18
The components of Esoxx are two well-known physio-
logic substances. Hyaluronic acid is a widespread, biolog-
ically active substance, which regulates cellular function
through interaction with speciﬁc receptors.19 It is a mul-
tifunctional, high molecular weight glycosaminoglycan,
component of the majority of extracellular matrices and
involved in several key physiologic processes, including
wound repair and regeneration, morphogenesis and
matrix organisation.20 The biological roles of hyaluronic
acid are in part dependent on its hydrophilic and hydro-
dynamic properties, which allow it to retain water and
play a structural role. Indeed, hydrogels (cross-linked
hydrophilic polymers) have been used as scaffolds to
allow tissue repair or regeneration at sites of injury,
being degraded by tissue enzymes after repair is com-
pleted.19 Low molecular weight hyaluronic acid is pro-
angiogenic, induces the formation of new blood vessels
and activates a signal transduction pathway leading to
endothelial cell proliferation and migration. In contrast,
native high molecular weight hyaluronic acid is anti-
angiogenic and will inhibit blood vessel formation.19
Topic hyaluronic acid formulations are employed to treat
recurrent aphthous ulceration of the oral mucosa21, 22
with fast symptom relief, to which the dose-dependent
anti-inﬂammatory activity of the compound23 may also
contribute.
Chondroitin sulphate is a natural glycosaminoglycan,
present in the extracellular matrix surrounding cells,
especially in the cartilage, skin, blood vessels, ligaments
and tendons, where it forms an essential component of
proteoglycans.24 Current evidence shows that chon-
droitin sulphate fulﬁls important biological functions in
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inﬂammation, cell proliferation, differentiation, migra-
tion, tissue morphogenesis, organogenesis, infection and
wound repair.25 These effects are related to the capacity
of chondroitin sulphate to interact with a wide variety of
molecules including (but not limited to) matrix mole-
cules, growth factors, protease inhibitors, cytokines,
chemokines and adhesion molecules via nonspeciﬁc/
speciﬁc saccharide domains within the chains.25 The
compound is endowed with immune-modulatory,26 anti-
inﬂammatory25, 26 and antioxidant27 properties. Along
with nonspeciﬁc interactions, chondroitin sulphate may
display speciﬁc binding to bioactive molecules, such as
pepsin. Peptic activity is indeed reduced both in vitro28
and in vivo29, 30, and treatment of peptic ulcer with
chondroitin sulphate has been attempted in the past.31
Poloxamer 407 (ethylene oxide and propylene oxide
blocks) is a hydrophilic non-ionic surfactant, which
shows thermo-reversible properties of the utmost interest
in optimising drug formulation (ﬂuid state at room tem-
perature, facilitating administration and gel state above
sol–gel transition temperature at body temperature, pro-
moting prolonged release of pharmacological agents).32
Poloxamer 407 formulations lead to enhanced solubilisa-
tion of poorly water-soluble drugs and prolonged release
proﬁle for many galenic applications.33 The poloxamer
407 adhesive properties are used to lengthen residence
time of agents in the gastrointestinal tract. Good adhe-
sion in the oesophagus with efﬁcient diffusion of the
drug into the mucosa was observed in the mouse, by
means of an optical ﬁbre spectroﬂuorimetric method.32
According to European Council Directive 93/42/
EEC,34 the National Health Institute in Rome classiﬁed
this bioadhesive formulation as class III medical device,
intended for use in human beings for the purpose of
treatment or alleviation of disease. Typically, the medical
device function is achieved by physical means (including
mechanical action, physical barrier, replacement of or
support to organs or body functions).
An ex vivo experimental study on a swine model
showed that perfusion of the oesophageal lumen with this
medical device is able to prevent the increase in mucosal
permeability induced by acid and/or pepsin.35 With these
data at hand, two double-blind, placebo-controlled stud-
ies demonstrated that short-term Esoxx treatment
achieves a signiﬁcant and quick symptom relief both in
patients with erosive36 or non-erosive reﬂux disease.37
In this prospective, double-blind, placebo-controlled
trial the efﬁcacy and safety of Esoxx, combined to acid
suppression, vs. acid suppression alone, was evaluated in
patients with NERD, diagnosed merely as endoscopy-
negative reﬂux disease. This was selected to mirror the
clinical practice, outside the referral centres, where
advanced investigations are not available.
PATIENTS AND METHODS
Non-erosive reﬂux disease patients with typical reﬂux
symptoms were enrolled in the study. They were of both
sexes, and age ranged from 18 to 75 years. Two of the
following symptoms, for example heartburn, acid regur-
gitation, retrosternal pain and acid taste in the mouth,
should have been present from at least 3 months and at
least three times per week in the month preceding the
study screening visit. The diagnosis of NERD was based
on the absence of macroscopic lesions of distal oesopha-
geal mucosa at endoscopy,3, 4 performed within
6 months from the screening visit, and by the positivity
of a validated questionnaire (Reﬂux Disease Question-
naire, RDQ),38 that is an RDQ score ≥8.39 In accordance
with the NICE Guidelines40 and to avoid interference
with the rapid urease test,41 routinely performed during
endoscopy, patients were free from anti-secretory medi-
cation (either a PPI or an H2RA) for at least 2 weeks.
Exclusion criteria were the presence of erosive
oesophagitis or Barrett’s oesophagus, gastric or duodenal
ulcer, previous gastric or major GI surgery, atopy or
food intolerance, thyroid diseases, diabetes or metabolic
syndrome. Moreover, pregnant, lactating or fertile
women (without contraception) were also excluded.
Study design
The study was multicenter, randomised, double-blind,
placebo-controlled with parallel groups. Sixteen Italian
hospitals were involved, and each of them obtained the
approval of the respective ethical committee.
The trial was performed according to the International
Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human
Use (ICH), guidelines for Good Clinical Practice
(GCP)42 and the Declaration of Helsinki (1996 version,
amended October 2000).43
Patients eligible for the study gave informed and written
consent and were asked to start a 15-day (2 days) run
in/wash out period, during which any (prescription or
OTC) therapy was discontinued (visit 1). The only medi-
cations permitted were antacids or alginate-containing for-
mulations in case of symptom occurrence. At visit 2,
patients were randomised – according to a computer-gen-
erated sequence – to receive one standard dose of a PPI
(30 min before breakfast) + 10 mL (1 stick) of Esoxx One
(single dose stick formulation) or placebo (with the same
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taste and viscosity, packed in identical, sequentially num-
bered, containers) q.d.s., that is 1 h after each daily meal,
and at bedtime for a 14-day treatment period. The alloca-
tion sequence was generated by LB Research (contract
research organisation), while enrolment and assignment of
participants to a given treatment were performed by the
principal investigator of the study centres (see
Appendix 1). During the study period, daily symptom dia-
ries, recording the presence or absence of each symptom
during the day and the night, were ﬁlled by each patient.
Before (visit 2) and after this short course of therapy (visit
3), frequency and severity of NERD symptoms were evalu-
ated using the same RDQ questionnaire. Health-related
quality of life (HRQL) was also assessed using the SF-36
questionnaire.44 Both questionnaires were administered by
physicians, who were unaware of the treatment given.
Results of each item were compared with those of pub-
lished data for the Italian normative sample.45 Pre- and
post-treatment results for each item were also compared.
The study design and the detailed assessment schedule can
be found in the Table S1.
Safety and tolerability were assessed by recording all the
adverse events, deﬁned as any unfavourable or unintended
symptom and/or sign, considered to be casually related to
the drug(s) used in the study. The palatability was evalu-
ated after each drug administration, according to a 4-item
scale (excellent, good, irrelevant and bad). Hence, there
were 4 per day 9 15 days evaluations for each patient.
Finally, patients’ compliance was deﬁned as the per-
centage of the test drug used, obtained by counting the
returned medications at visit 3. A treatment compliance
of 80–120% was considered acceptable.
The European Clinical Trials Database (EudraCT),
launched by the European Medicines Agency (EMA),
does not accept clinical trials investigating medical
devices, but refers to the procedures in place in the
Country, where the clinical trial is conducted. Accord-
ingly, the Clinical Trial Protocol was registered (Protocol
code: Esoxx-NERD/001/2012) at the Italian Ministry of
Health, and the beginning of the trial (i.e. the inclusion
of the ﬁrst patient), as well as the end of the trial (i.e.
the last evaluation of the last included patient), was noti-
ﬁed to the regulatory authorities.
Statistical analysis
The primary endpoint was the treatment efﬁcacy analy-
sis, which was calculated as the proportion of patients
with at least 3-point reduction of the total symptom
score (TSS). This was calculated by collecting and com-
puting the intensity of each patient’s symptom (on the
basis of the RDQ questionnaire at the ﬁnal visit) and
comparing it with the baseline values, obtained at the
end of the run in/wash out period (visit 2). Typical
symptoms were evaluated according to a 5-degree Likert
scale46: 0 = no symptom, 1 = poorly troublesome symp-
toms, 2 = troublesome symptoms, 3 = very troublesome
symptoms, interfering with daily activities, 4 = intolera-
ble symptoms, not permitting any daily activity.
There were four different secondary endpoints: (i)
number of patients with 50% reduction of TSS at ﬁnal
visit, (ii) number of patients with TSS reduction at the
ﬁnal visit, (iii) change TSS after treatment and (iv)
HRQL physical and mental items according to the SF-36
questionnaire, which were calculated via a web-based
program47 and presented as radar plots or spidergrams.48
Changes in the severity and frequency of each symptom
(heartburn, acid regurgitation, retrosternal pain, acid
taste in the mouth) were also evaluated.
The intention-to-treat (ITT) population included all
randomised patients, who took at least one dose of med-
ication while per protocol (PP) analysis was performed
on all randomised patients, who concluded the treat-
ment, with an adequate compliance rate and without any
protocol violation. The former analysis was used to eval-
uate the primary endpoint and the latter for both pri-
mary and secondary endpoints. The safety population
included all randomised patients, who took at least one
dose of the study drugs.
Chi-squared and Fisher’s exact test, two tails, were
used to compare percentages of values for primary and
secondary endpoints, while arithmetic means and fre-
quencies were assessed by means of 95% conﬁdence
intervals (CIs).49 All the calculations were performed
using the PRISM 6.0 software (GraphPad, San Diego,
CA, USA), running on a MAC.
The sample size was calculated on the basis of the
reduction of NERD TSS by 3 points at ﬁnal visit and
assuming a rate of 10% improvement in the placebo
group and 30% in the Esoxx arm. A power level of 80%
with a signiﬁcance value ≤0.05 (two-sided Fisher’s exact
test) required a sample size of 70 patients for each group.
Taking into account a 12% of non-evaluable patients, the
sample was raised to 80 patients. The estimation was
made, using the STATA (Version 13, StataCorp LP, College
Station, TX, USA) for MAC.
RESULTS
In the 16 centres involved in the study, 172 NERD
patients were screened and 154 out of them were ran-
domised to treatment, 76 in the Esoxx group and 78 in
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the placebo one. Among them, 18 patients were consid-
ered dropouts for various reasons: eight for adverse
events, two for treatment failure and eight denied con-
sent (Figure 1).
Table 1 shows the baseline demographics and the clin-
ical characteristics of the groups studied, in the ITT pop-
ulation. There were no statistical differences among the
different characteristics of the recruited patients in the
two arms.
The compliance, deﬁned as mean number (s.d.) of
sticks taken, was similar (P = NS) in the two arms of
treatment, that is 90.9  22.9 vs. 90.2  20.7 in the
Esoxx and placebo groups, respectively.
As regards the primary endpoint, Table 2 (ITT analy-
sis) shows that the proportion of patients with TSS
reduction of at least 3 points at ﬁnal visit was higher in
the Esoxx than in the placebo group and the difference
was always signiﬁcant. Also the proportion of patients
with 50% TSS reduction at visit 3, as secondary end-
point, resulted to be signiﬁcantly higher (P < 0.042) in
the Esoxx (38.2%) than in the placebo (23.1%) group
(Table 2). In addition, number of patients with TSS
reduction at the ﬁnal visit was signiﬁcantly higher in
Esoxx than in placebo arm (P < 0.026). Finally, TSS after
treatment improved more with Esoxx than with placebo
treatment (P < 0.011). Similar results were obtained in
the PP population (Table S2). As shown in Table 3, all
the symptoms evaluated subsided with both treatments,
but the amelioration of heartburn and especially regurgi-
tation was more marked with Esoxx combined with
Excluded (n = 4)
♦ Not meeting inclusion criteria (n = 1)
♦ Declined to participate (n = 3)
♦ Other reasons (n = 0)
Analysed ITT population (n = 76)
Analysed ITT population (n = 76)
♦Excluded from analysis (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention due
To adverse events (n = 5)
Allocated to Esoxx (n = 76)
♦Received allocated intervention (n = 76)
♦Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 13)
3 due to adverse events, 8 due to consent
withdrawn, 2 due to lack of efficacy
Allocated to Placebo (n = 78)
♦Received allocated intervention (n = 71)
♦Did not receive allocated intervention (n = 7)
Analysed ITT population (n = 78)
Analysed ITT population (n = 71)
♦ Excluded from analysis (not 
receiving allocated intervention (n = 7)
Randomised (n = 154)
Assessed for eligibility
(n = 172)
Allocation
Analysis
Follow-up
Enrollment
Figure 1 | Consort 2010 ﬂow diagram.
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PPIs. The therapeutic gain with Esoxx was 20.5%, 15.3%
and 10.2% for TSS (symptom severity), heartburn and
regurgitation incidence, respectively.
Finally, the quality of life, evaluated by means of the
SF-36 items, improved with both treatments (Figure 2).
Indeed, 2 weeks after therapy the SF-36 items become clo-
ser to those of the Italian normative sample.45 However,
the improvements in General Health Perception and the
Social Function items were signiﬁcantly (P < 0.01 and
P < 0.02, respectively) better after Esoxx plus PPI therapy.
The safety of Esoxx was very good, as the total num-
ber of adverse events was similar to that of placebo and
there were no serious adverse events in any treatment
arms (Table 4). The most frequent manifestations per-
tained to the gastrointestinal tract (nausea, ﬂatulence,
bloating, dyspepsia, etc.) and respiratory organs (cough,
rhinitis, pharyngeal disorders) (Table 5).
On the basis of the total number of evaluations col-
lected (n = 7230), in 92% of Esoxx administrations,
palatability was considered acceptable, independently of
the intake time (be it during the day or at bedtime)
while the same held true for 90% of placebo administra-
tions (P = NS). The distribution of these evaluations is
shown in Figure 3.
DISCUSSION
The results of this study show that, when mucosal pro-
tection is added to acid suppression, a signiﬁcantly
higher number of NERD patients obtained symptom
relief with combination therapy. Indeed, both the pri-
mary and secondary endpoints were achieved in a larger
proportion of subjects.
Although PPIs are effective in obtaining symptom
relief in both erosive and NERD,50 their efﬁcacy for the
relief of regurgitation is modest, and considerably lower
than that achieved for heartburn.51 In addition,
although not as frequent as previously suggested,7 PPI-
refractory heartburn, occurring more commonly in
NERD than in erosive disease, does exist. Some 20%
(range 15–27%) of correctly diagnosed and
Table 1 | Baseline characteristics of NERD patients receiving Esoxx or placebo, combined with PPIs
Esoxx (n = 76) Placebo (n = 78) P value
Female, N (%) 48 (63.2%) 46 (59.0%) NS
Age (years), mean  s.d. 45.45  14.98 45.51  13.37 NS
Range (min–max) 18–81 24–75
BMI (kg/m2) 23.87  3.10 23.77  3.23 NS
GERD total symptom score 7.30  2.4 7.19  2.6 NS
Proportion of patients with ≥3 GERD symptoms (%) 44.0 41.0 NS
Heartburn 84.2 85.9
Retrosternal pain 53.9 49.3
Acid regurgitation 69.7 66.2
Acid taste in the mouth 60.5 59.2
Past treatment with PPIs (%) 56.6 64.8 NS
Past treatment with other anti-GERD therapies (%) 23.7 29.6 NS
Table 2 | Effect of Esoxx, combined with PPI therapy, on primary and secondary endpoints in patients with NERD: ITT
analysis
Trial endpoints
PPI + Esoxx PPI + Placebo
P valuen/N % n/N %
Primary
No of patients with TSS reduction of at least 3 points 40/76 52.6 25/78 32.1 0.01
Secondary
No of patients with 50% reduction of TSS 29/76 38.2 18/78 23.1 0.042
No of patients with TSS reduction at ﬁnal visit 60/76 78.9 44/78 56.4 0.003
TSS (s.d.) before and after treatment Before After Before After
8.53  2.6 5.42  2.1 8.03  2.7 6.49  2.6
Change (s.d.) in TSS 3.11  3.1 1.54  3.0 0.002
TSS, total symptom (heartburn, retrosternal pain, regurgitation, acid taste) score.
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appropriately treated patients do not respond to PPI
therapy at standard doses.52
Various underlying mechanisms have been shown to
contribute to the failure of PPI treatment. They include
patient-related (e.g. lack of compliance), physician-related
(e.g. misdiagnosis) and drug-related (e.g. short duration of
action) mechanisms.53, 54 At the present time, much
current research is focused on weakly acidic reﬂux55 and
oesophageal hypersensitivity.56 The pH-impedance tech-
nique has been increasingly used to explore the underlying
pathophysiology in PPI-resistant patients. Several groups
of investigators have indeed shown that weakly acidic
reﬂux plays a major role in PPI-resistant erosive and non-
erosive disease.57pH-impedance monitoring has also
Table 3 | Effect of Esoxx, combined with PPI therapy, on (a) severity and (b) frequency of GERD symptoms in patients
with NERD: ITT analysis
Symptom
PPI + Esoxx, mean
score  s.d.
Adjusted mean
change (95% CI)
PPI + placebo, mean
score  s.d.
Adjusted mean
change (95% CI)
P value Esoxx
vs. placebo
Before
therapy
After
therapy
Before
therapy
After
therapy
(a)
Heartburn 1.80  1.1 0.72  0.8 1.131 (1.340 to 0.922) 1.99  1.0 1.09  1.0 0.836 (1.034 to 0.638) 0.0319
Regurgitation 1.84  1.1 0.64  0.8 1.095 (1.280 to 0.911) 1.53  1.1 0.94  1.0 0.685 (0.861 to 0.509) 0.0009
Retrosternal
pain
1.36  1.2 0.42  0.7 0.852 (1.023 to 0.682) 1.15  1.2 0.59  0.8 0.612 (0.775 to 0.449) 0.0323
Acid taste in
the mouth
1.53  1.1 0.63  0.8 0.754 (0.968 to 0.541) 1.3  1.1 0.8  1.0 0.494 (0.696 to 0.291) 0.0623
(b)
Heartburn 3.08  1.7 1.38  1.5 1.719 (2.083 to 1.354) 3.23  1.5 1.94  1.6 1.229 (1.578 to 0.883) 0.0408
Regurgitation 2.92  1.7 1.23  1.5 1.562 (1.892 to 1.233) 2.60  1.8 1.63  1.7 1.021 (1.332 to 0.710) 0.0128
Retrosternal
pain
2.14  1.8 0.82  1.3 1.232 (1.511 to 0.952) 1.86  1.7 1.03  1.3 0.896 (1.163 to 0.630) 0.0676
Acid taste in
the mouth
2.57  1.7 1.16  1.5 1.285 (1.640 to 0.930) 2.38  1.8 1.53  1.7 0.876 (1.213 to 0.540) 0.0790
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Figure 2 | HRQL measured in NERD patients before and after 2-week treatment with Esoxx or Placebo combined to
PPIs. Note that, after treatment, the SF-36 items are close to those of the Italian normative sample.
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allowed identiﬁcation of a previously unknown subgroup
of patients, namely those with normal oesophageal pH-
impedance recording, but a positive association between
symptoms and non-acidic reﬂux episodes, that is patients
who are hypersensitive to non-acidic reﬂux.57 Finally, this
methodology has enabled a better differentiation between
patients with NERD and those with functional heart-
burn.58 It is therefore evident that different patient sub-
groups belong to NERD, which is indeed an umbrella
term. Among them, only patients with true NERD or acid
hypersensitive oesophagus (now called reﬂux hypersensi-
tivity, according to the Rome IV criteria59) are expected to
display a satisfactory symptomatic response to acid sup-
pression therapy with a PPI. On the contrary, subjects
hypersensitive to non-acid reﬂux or those with functional
heartburn (which – together with reﬂux hypersensitivity –
does not pertain anymore to the realm of GERD) will
obviously be nonresponsive to anti-secretory drugs.60
In patients with NERD, who are refractory to a cor-
rectly performed PPI therapy, the lack of symptom relief
could be due to persistence of microscopic mucosal alter-
ations induced by weakly acidic reﬂux,61 by pepsin or
other components of the reﬂuxate62 and underlined by
an impaired mucosal integrity.63 Current pharmacologic
approaches to address this clinically challenging condi-
tion are limited. Reﬂux inhibitors represent a promise
unfulﬁlled,64 effective prokinetics are lacking 65 and anti-
depressants, despite being effective in selected patients,66
give rise to adverse events in up to 32% of patients.67
A better approach to patients with NERD should be
therefore making a more precise diagnosis, by adding a
functional evaluation (e.g. pH or pH-impedance record-
ing) to negative endoscopy. When this has been done,
the estimated complete symptom response rate after PPI
therapy appeared comparable to that observed in
patients with GERD.68 Including biopsy (and subsequent
histology) of the ‘macroscopically normal’ mucosa during
endoscopic examination61 would be ideal. It is evident,
however, that this approach, being time-consuming and
costly, is not achievable in the everyday clinical practice.
An alternative, easier, approach could be combination
therapy, that is adding drugs with different mechanism
(s) of action to PPIs. Up to now, only irsogladine (a
mucosal protective compound)69 and alginate-containing
formulations70, 71 – given as add-on medications –
proved to be capable of improving symptom control in
NERD patients. The addition of mosapride (a prokinetic
compound) to PPIs does not add any beneﬁt72, 73 unless
NERD patients display a delay in gastric emptying.74
The mucosal protective device, Esoxx, was shown to be
capable of achieving a signiﬁcant and quick symptom
relief in patients with NERD in this and a previous trial.37
Its amelioration of regurgitation severity and frequency is
of clinical interest, taking into account the negligible effect
Table 4 | Adverse events in NERD patients, included in
the ITT analysis, receiving PPI + Esoxx or PPI + placebo
Esoxx
(n = 76)
Placebo
(n = 71) P value
Total number of
unique AEs
32 14 NS
Total number
of AEs
35 20 NS
Total number of
patients with at
least one AE
18 (23.7) 11 (15.5) NS
Total number of
unique drug-related
AEs
23 13 NS
Total number of
drug-related AEs
24 19 NS
Total number of patients
with at least one
related AEs
13 (17.1) 10 (14.1) NS
Total number of
serious AEs
0 0 NS
Total number of patients
with at least one AE
leading to discontinuation
5 (6.6) 3 (3.8) NS
Values within parenthesis are expressed as percentage. AE,
adverse event.
Table 5 | Patients, treated with PPI combined with
Esoxx or placebo, with at least one TEAEs classiﬁed for
system organ class (SOC) – safety analysis
SOC
Esoxx
(n = 76)
Placebo
(n = 71)
Patients with at least
one TEAE
18 (23.7) 11 (15.5)
Gastrointestinal disorders 13 (17.1) 7 (9.9)
Respiratory, thoracic,
mediastinal disorders
(cough, rhinitis, throat
irritation, pharyngeal
disorders)
4 (5.3) 1 (1.4)
Nervous system disorders
(dysgeusia, headache,
migraine)
3 (3.9) –
Cardiac disorders (palpitations,
tachycardia)
1 (1.3) 1 (1.4)
Ear and labyrinth (vertigo) 1 (1.3) –
General disorders (hypertension) 1 (1.3) –
Infections and infestations 1 (1.3) 3 (4.2)
Values within parenthesis are expressed as percentage.
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PPIs have on this cardinal symptom of reﬂux disease.51, 63
As shown by a small study,36 this formulation may well be
effective also in patients with erosive disease, in whom its
protective and reparative properties would favour healing
of oesophageal mucosal lesions.
The synergistic effect of Esoxx with PPIs, shown in
this study, suggests that mucosal protection, routinely
added to acid suppression, could extend to a larger num-
ber of patients with NERD both symptom relief and
improvement of HRQL, thus reducing the incidence of
treatment failures. PPIs achieve a symptom relief, which
increases over time both in erosive and non-erosive dis-
ease. This has been further shown by the studies com-
paring PPIs (namely esomeprazole) with P-CABs
(namely linaprazan).75, 76 It may well be that this com-
bined approach achieves at 2 weeks the same symptom
relief, obtained with PPIs at 4 weeks. However, for those
patients asking for quick symptom relief, this time-
dependent therapeutic gain could be worthwhile from
their own perspective.
The present study has intrinsic limitations. As func-
tional investigation (i.e. pH-impedance recording) was
not performed, the population studied included patients
with functional heartburn and reﬂux hypersensitivity. In
addition, although adequately powered to show a signiﬁ-
cant effect, this was a relatively small trial. A larger study
in patients with PPI-resistant NERD as well as a trial in
patients with extra-oesophageal symptoms is worthwhile.
Despite recent research has established the sites and
mechanisms underlying oesophageal mucosal defence, its
enhancement is very rarely pursued in clinical practice.
Drugs able to strengthen mucosal defence do exist, but
they have not been studied in well designed clinical tri-
als.63 Due their high efﬁcacy in reﬂux disease, it is unli-
kely that these drugs represent a real alternative to PPIs.
However, their use in less severe disease or as add-on
medications to PPIs could be useful. Furthermore, used
in the long term, these mucosal protective compounds
might prolong remission and delay relapse.
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